Protocol Ledger

NCT06051617 · Phase III · RECRUITING

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Interventional Phase III clinical trial protocol NCT06051617 sponsored by Gilead Sciences in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-07 Enrollment: 402 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06051617
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)402 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06051617
Protocol FieldVerified Registry Value
NCT IdentifierNCT06051617
Consolidated Lead SponsorGilead Sciences
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment402 participants (ESTIMATED)
Registered Start Date2023-09-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI